BIO Bio-Rad Laboratories Inc

Price (delayed)

$507.84

Market cap

$15.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.07

Enterprise value

$15.81B

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, ...

Highlights
The company's quick ratio has surged by 105% QoQ and by 67% YoY
Bio-Rad Laboratories's gross profit has increased by 8% YoY
The EPS has plunged by 102% YoY and by 102% from the previous quarter
The net income has shrunk by 102% YoY and by 102% QoQ

Key stats

What are the main financial stats of BIO
Market
Shares outstanding
29.94M
Market cap
$15.21B
Enterprise value
$15.81B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.49
Price to sales (P/S)
5.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.46
Earnings
Revenue
$2.9B
EBIT
-$224.87M
EBITDA
-$224.87M
Free cash flow
$459.11M
Per share
EPS
-$3.07
Free cash flow per share
$15.34
Book value per share
$340.2
Revenue per share
$96.74
TBVPS
$460.39
Balance sheet
Total assets
$14.37B
Total liabilities
$4.19B
Debt
$1.4B
Equity
$10.18B
Working capital
$2.66B
Liquidity
Debt to equity
0.14
Current ratio
5.1
Quick ratio
3.92
Net debt/EBITDA
-2.67
Margins
EBITDA margin
-7.8%
Gross margin
56.8%
Net margin
-3.5%
Operating margin
18.4%
Efficiency
Return on assets
-0.6%
Return on equity
-0.8%
Return on invested capital
-1.5%
Return on capital employed
-1.6%
Return on sales
-7.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
0.45%
1 week
9.53%
1 month
-2.1%
1 year
-19.63%
YTD
-32.79%
QTD
-9.83%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.9B
Gross profit
$1.64B
Operating income
$531.99M
Net income
-$101.13M
Gross margin
56.8%
Net margin
-3.5%
The net income has shrunk by 102% YoY and by 102% QoQ
The net margin has dropped by 102% since the previous quarter and by 102% year-on-year
BIO's operating income is up by 22% year-on-year and by 9% since the previous quarter
BIO's operating margin is up by 14% year-on-year and by 10% since the previous quarter

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
P/E
N/A
P/B
1.49
P/S
5.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.46
The EPS has plunged by 102% YoY and by 102% from the previous quarter
The equity has contracted by 25% from the previous quarter and by 4% YoY
BIO's P/B is 17% below its 5-year quarterly average of 1.8 and 7% below its last 4 quarters average of 1.6
The stock's price to sales (P/S) is 24% less than its last 4 quarters average of 6.9 but 7% more than its 5-year quarterly average of 4.9
The revenue has grown by 7% YoY

Efficiency

How efficient is Bio-Rad Laboratories business performance
The ROS has plunged by 104% from the previous quarter and by 104% YoY
The company's return on invested capital has shrunk by 104% QoQ and by 103% YoY
Bio-Rad Laboratories's ROA has plunged by 102% from the previous quarter and by 102% YoY
The ROE has dropped by 102% since the previous quarter and by 102% year-on-year

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The company's quick ratio has surged by 105% QoQ and by 67% YoY
The company's current ratio has surged by 75% QoQ and by 43% YoY
The debt is 86% smaller than the equity
The equity has contracted by 25% from the previous quarter and by 4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.